Endothelial LRP1-A Potential Target for the Treatment of Alzheimer's Disease

被引：2
|
作者：
Storck, Steffen E. [1 ]
Pietrzik, Claus U. [1 ]
机构：
[1] Johannes Gutenberg Univ Mainz, Inst Pathobiochem, Mol Neurodegenerat, Univ Med Ctr, Duesbergweg 6, D-55099 Mainz, Germany
来源：
PHARMACEUTICAL RESEARCH | 2017年 / 34卷 / 12期
关键词：
Alzheimer's disease; angiopeps; beta-amyloid; blood-brain barrier; choroid plexus; drug delivery; LRP1; targeting; RECEPTOR-RELATED PROTEIN; BLOOD-BRAIN-BARRIER; AMYLOID PRECURSOR PROTEIN; CENTRAL-NERVOUS-SYSTEM; A-BETA OLIGOMERS; DRUG-DELIVERY; APOLIPOPROTEIN-E; IN-VITRO; CEREBROSPINAL-FLUID; POLYMERIC NANOPARTICLES;
D O I：
10.1007/s11095-017-2267-3
中图分类号：
O6 [化学];
学科分类号：
0703 ;
摘要：
The accumulation of the neurotoxin beta-amyloid (A beta) is a major hallmark in Alzheimer's disease (AD). A beta homeostasis in the brain is governed by its production and various clearance mechanisms. Both pathways are influenced by the ubiquitously expressed low-density lipoprotein receptor-related protein 1 (LRP1). In cerebral blood vessels, LRP1 is an important mediator for the rapid removal of A beta from brain via transport across the blood-brain barrier (BBB). Here, we summarize recent findings on LRP1 function and discuss the targeting of LRP1 as a modulator for AD pathology and drug delivery into the brain.
引用
收藏
页码：2637 / 2651
页数：15
相关论文
共 50 条
  • [31] Natural Scaffolds with Multi-Target Activity for the Potential Treatment of Alzheimer's Disease
    Piemontese, Luca
    Vitucci, Gabriele
    Catto, Marco
    Laghezza, Antonio
    Perna, Filippo Maria
    Rullo, Mariagrazia
    Loiodice, Fulvio
    Capriati, Vito
    Solfrizzo, Michele
    MOLECULES, 2018, 23 (09):
  • [32] Endothelial dysfunction: A potential therapeutic target for geriatric depression and brain amyloid deposition in Alzheimer's disease?
    Isingrini, Elsa
    Desmidt, Thomas
    Belzung, Catherine
    Camus, Vincent
    CURRENT OPINION IN INVESTIGATIONAL DRUGS, 2009, 10 (01) : 46 - 55
  • [33] Copper-Induced Upregulation of MicroRNAs Directs the Suppression of Endothelial LRP1 in Alzheimer's Disease Model
    Hsu, Heng-Wei
    Rodriguez-Ortiz, Carlos J.
    Lim, Siok Lam
    Zumkehr, Joannee
    Kilian, Jason G.
    Vidal, Janielle
    Kitazawa, Masashi
    TOXICOLOGICAL SCIENCES, 2019, 170 (01) : 144 - 156
  • [34] DAPK1: a Novel Pathology and Treatment Target for Alzheimer's Disease
    Xu, Ling-zhi
    Li, Bing-qiu
    Jia, Jian-ping
    MOLECULAR NEUROBIOLOGY, 2019, 56 (04) : 2838 - 2844
  • [35] DAPK1: a Novel Pathology and Treatment Target for Alzheimer’s Disease
    Ling-zhi Xu
    Bing-qiu Li
    Jian-ping Jia
    Molecular Neurobiology, 2019, 56 : 2838 - 2844
  • [36] The potential for BACE1 inhibitors in the treatment of Alzheimer's disease
    Hussain, I
    IDRUGS, 2004, 7 (07) : 653 - 658
  • [37] DYRK1A inhibition as potential treatment for Alzheimer's disease
    Stotani, Silvia
    Giordanetto, Fabrizio
    Medda, Federico
    FUTURE MEDICINAL CHEMISTRY, 2016, 8 (06) : 681 - 696
  • [38] MicroRNAs as a New Target for Alzheimer's Disease Treatment
    Shademan, Behrouz
    Avci, Cigir Biray
    Karamad, Vahidreza
    Sogutlu, Fatma
    Nourazarian, Alireza
    MICRORNA, 2023, 12 (01) : 3 - 12
  • [39] Butyrylcholinesterase: a target in the cholinergic treatment of Alzheimer's disease
    Potkin, SG
    PRIMARY CARE PSYCHIATRY, 2004, 9 (03): : 83 - 87
  • [40] An Update on Autophagy as a Target in the Treatment of Alzheimer's Disease
    Sose, Parnika Mohan
    Doshi, Gaurav Mahesh
    Kale, Pravin Popatrao
    CURRENT DRUG TARGETS, 2023, 24 (07) : 547 - 567
12345